Bioventus Inc. (BVS) stock

BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 26, 2026Last filing: 10-Q on Nov 2, 2026Score 14/3033% below fair value

$10.86−0.13 (-1.18%)

Close on Nov 12, 2026Market cap $913.24MP/E 13.6Yield –

Bioventus statistics

100 measures from SEC filings and the closing price. Hover a name for the formula; the last column is the median of companies in the same industry group.

Important dates

Next earnings: Mar 4, 2027 (estimated, before the open)
Last ex-dividend date: No dividends
Fundamentals through: Sep 26, 2026
Share price as of: Nov 11, 2026

Valuation ratiosIndustry

Market Cap: $924.17M; $522.32M
Enterprise Value: $1.17B; $447.89M
PE Ratio: 13.74; 30.23
PS Ratio: 1.58; 3.10
PB Ratio: 3.84; 3.22
P/FCF Ratio: 10.87; 26.72
P/OCF Ratio: 10.57; 22.88

Enterprise valuationIndustry

EV / Sales: 2.01; 2.86
EV / EBITDA: 14.37; 18.87
EV / EBIT: 20.71; 24.48
EV / FCF: 13.82; 28.69

Share statisticsIndustry

Shares Outstanding: 84M; 43M
Shares Change (YoY): 5.12%; 3.22%
Float: 60M; 37M
Shares Held by Insiders: 29.0%; 10.5%
Shares Held by Institutions: 71.2%; 60.2%

Short sellingIndustry

Short Interest: 3M; –
Short Interest Change: -4.88%; -2.57%
Short % of Float: 5.06%; 5.12%
Short % of Shares Outstanding: 3.59%; 3.98%
Days to Cover: 6.62; 3.94

Stock price statisticsIndustry

52-Week High: $15.89; –
52-Week Low: $6.47; –
20-Day Moving Average: $13.04; –
50-Day Moving Average: $13.28; –
200-Day Moving Average: $11.03; –
Average True Range (14): $0.73; –
Price Change (1 Week): -3.77%; -0.66%
Price Change (1 Month): -19.0%; -0.65%
Price Change (3 Months): -20.9%; -6.51%
Price Change (6 Months): 5.67%; 0.80%
Price Change (YTD): 47.7%; 1.08%
Price Change (1 Year): 46.7%; -2.00%
Price Change (3 Years): 197.0%; 9.00%
Price Change (5 Years): -30.6%; -45.3%
Average Volume (10 Days): 877,886; –
Average Volume (20 Days): 652,912; –
Average Volume (90 Days): 615,098; –
Relative Volume: 0.74; 0.81
Relative Strength Index (14): 34.9; 50.1
Volatility (1 Year): 53.2%; 64.2%
Beta (5 Years): 0.91; 1.05

MarginsIndustry

Gross Margin: 68.7%; 55.9%
Operating Margin: 9.69%; -5.17%
Pretax Margin: 6.85%; -2.55%
Profit Margin: 9.78%; -9.23%
EBITDA Margin: 14.0%; -2.82%
FCF Margin: 14.5%; 0.40%

Returns on capitalIndustry

Return on Equity (ROE): 28.2%; -17.0%
Return on Assets (ROA): 8.33%; -12.2%
Return on Invested Capital (ROIC): 12.8%; -3.11%
Return on Capital Employed (ROCE): 11.0%; -8.13%

Financial positionIndustry

Current Ratio: 1.68; 2.45
Quick Ratio: 1.07; 1.53
Debt / Equity: 0.96; 0.42
Debt / EBITDA: 2.81; 2.19
Debt / FCF: 2.70; 3.62
Net Debt / EBITDA: 2.44; 1.53

GrowthIndustry

Revenue Growth (YoY): 3.87%; 9.27%
Net Income Growth (YoY): 655.0%; 13.4%
EPS Growth (YoY): 627.3%; 15.1%
FCF Growth (YoY): 58.9%; 7.64%
Revenue Growth (3Y CAGR): 3.52%; 7.08%
Revenue Growth (5Y CAGR): 12.1%; 11.8%

EfficiencyIndustry

Asset Turnover: 0.85; 0.59
Inventory Turnover: 2.04; 2.20
Revenue Per Employee: $629.72K; $330.60K
Profits Per Employee: $61.61K; -$41.39K
Employee Count: 930; 186
WACC: 8.91%; 9.76%

Income statement (TTM)Industry

Revenue: $585.64M; $106.81M
Gross Profit: $402.35M; $62.29M
Operating Income: $56.73M; -$4.10M
Pretax Income: $40.13M; -$1.69M
Net Income: $57.30M; -$6.19M
EBITDA: $81.72M; -$1.98M
EPS (Diluted): $0.80; -$0.08

Balance sheetIndustry

Cash & Short-Term Investments: $30.71M; $38.08M
Total Debt: $229.83M; $96.00M
Net Cash (Debt): -$199.12M; $3.73M
Net Cash Per Share: -$2.37; $0.24
Equity (Book Value): $240.50M; $63.44M
Book Value Per Share: $2.86; $3.26
Tangible Book Value: -$110.89M; $11.04M
Working Capital: $107.84M; $56.85M

Cash flow (TTM)Industry

Operating Cash Flow: $87.43M; -$541.49K
Capital Expenditures: -$2.45M; -$3.69M
Free Cash Flow: $84.99M; -$387.37K
FCF Per Share: $1.01; -$0.01

Dividends and yieldsIndustry

Earnings Yield: 6.20%; -4.68%
FCF Yield: 9.20%; 0.25%
Buyback Yield: -0.31%; 0.78%
Shareholder Yield: -0.31%; 1.04%

Taxes and interestIndustry

Income Tax: -$24.20M; $1.63M
Effective Tax Rate: -60.3%; 18.3%

Scores and fair valueIndustry

Graham Number: $7.17; $38.11
Graham Upside: -34.7%; -57.0%
Altman Z-Score: 2.19; 2.54
Piotroski F-Score: 8; 5
Beneish M-Score: -2.77; -2.64

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.

Period	BVS	S&P 500	Difference	BVS per year	S&P 500 per year
1 month	-19.7%	-2.7%	−17.0 pts
3 months	-22.0%	-1.7%	−20.2 pts
Year to date	+46.0%	+11.9%	+34.1 pts
1 year	+42.0%	+12.0%	+30.0 pts
3 years	+208.5%	+78.2%	+130.3 pts	+45.6%	+21.2%
5 years	-31.4%	+73.2%	−104.7 pts	-7.3%	+11.6%

Short interest

Shares sold short and not yet covered, reported by brokers to FINRA twice a month. Latest settlement date Oct 30, 2026.

3M BVS shares were sold short on Oct 30, 2026, down 4.9% from the previous report, or 5.06% of the shares available to trade. At recent volumes it would take 6.6 days to buy them back. Over the last 20 sessions, 62.9% of the volume reported to FINRA was short selling.

Settlement date	Shares short	Change	Avg. daily volume	Days to cover
Oct 30, 2026	3,022,935	-4.9%	456,488	6.6
Oct 15, 2026	3,177,872	+0.5%	355,203	8.9
Sep 30, 2026	3,161,332	+7.9%	471,636	6.7
Sep 15, 2026	2,930,690	+13.6%	511,273	5.7
Aug 31, 2026	2,580,938	+10.6%	554,541	4.7
Aug 14, 2026	2,334,332	-7.9%	1,005,949	2.3
Jul 31, 2026	2,535,766	-7.1%	653,572	3.9
Jul 15, 2026	2,729,359	+24.9%	771,809	3.5
Jun 30, 2026	2,184,427	+13.2%	672,570	3.3
Jun 15, 2026	1,929,816	+4.8%	718,417	2.7
May 29, 2026	1,842,216	+16.9%	728,123	2.5
May 15, 2026	1,575,651	+7.5%	537,936	2.9